DALLAS - September 23, 2026 (NEWMEDIAWIRE) - An internationally recognized clinical researcher whose work has helped transform the treatment of chronic kidney disease will be recognized by the American Heart Association at its annual Scientific Sessions in November. Katherine R. Tuttle, M.D., executive director for research at Providence in Spokane, Washington, will receive the American Heart Association's 2026 Clinical Research Prize at the Association's Scientific Sessions 2026. The meeting, to be held Nov. 6-9, 2026, in Chicago, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. Dr. Tuttle will receive the award during the Presidential Session on Sunday, Nov. 8.

Dr. Tuttle also serves as professor of medicine at the University of Washington School of Medicine in Seattle and was the inaugural regional principal investigator at the Institute of Translational Health Sciences, also in Seattle. Her research focuses on diabetes, chronic kidney disease (CKD) and cardiovascular-kidney-metabolic (CKM) syndrome. Over more than three decades as a clinical and translational scientist, her pioneering work has helped transform the treatment of CKD by advancing therapies that reduce the risks of kidney failure, major adverse cardiovascular events and premature death in people with and without diabetes. She has played a leading role in studies that established SGLT2 inhibitors and GLP-1 receptor agonists as breakthrough therapies, and her research continues to advance the next generation of treatments for CKD and CKM conditions.

“Dr. Tuttle has fundamentally changed the care of patients living with chronic kidney disease and cardiovascular-kidney-metabolic conditions," said Manesh R. Patel, M.D., FAHA, the American Heart Association's 2026-2027 volunteer president, the Richard S. Stack, M.D. Distinguished Professor of Medicine, chief of the division of cardiology and vice president of heart and vascular services at Duke University in Durham, North Carolina. “Her visionary clinical research has deepened our understanding of the connection between kidney disease and cardiovascular disease, and helped advance an integrated approach to cardiovascular-kidney-metabolic health that recognizes the interrelated effects of kidney disease, cardiovascular disease, diabetes and obesity. She is an extraordinary physician-scientist whose leadership continues to shape the future of cardiovascular and kidney medicine.”

Dr. Tuttle’s research has spanned the full spectrum of translational science, from foundational physiologic and pre-clinical studies to landmark clinical trials and implementation research. She has served as a leading investigator for numerous breakthrough therapies targeting CKD and CKM conditions, including SGLT2 inhibitors, GLP-1 receptor agonists, next-generation incretin therapies, anti-inflammatory agents and aldosterone-targeted therapies. She also leads the CURE-CKD Registry, one of the nation's largest real-world databases of patients with chronic kidney disease, diabetes and hypertension, encompassing more than seven million health system patients with or at risk for chronic kidney disease across Providence and UCLA Health facilities in seven states.

Throughout her distinguished career, Dr. Tuttle has also provided national and international leadership in kidney and cardiovascular medicine. She has chaired major initiatives for the American Society of Nephrology, National Institutes of Health (NIH), International Society of Nephrology, Kidney Disease: Improving Global Outcomes (KDIGO), National Kidney Foundation and the American Diabetes Association, helping shape clinical practice and research priorities worldwide.

A longtime Heart Association volunteer, she has served on the Heart Association’s Council on the Kidney in Cardiovascular Disease, Scientific Publishing Committee, Awards Committee, Scientific Advisory Group, and as a Go Red for Women Ambassador. She also contributed to the writing groups for the scientific statement on cardiorenal protection with newer diabetes medications and its foundational presidential advisory and scientific statement defining cardiovascular-kidney-metabolic syndrome. Most recently, she served on the writing committee for the 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome.

“I am deeply honored to receive this recognition from the American Heart Association,” said Dr. Tuttle. “Throughout my career, I have focused on collaboration to advance clinical research and improve the lives of people living with cardiovascular, kidney and metabolic diseases.”

Dr. Tuttle’s scientific achievements have earned numerous honors, including the National Kidney Foundation’s Garabed Eknoyan Award in 2017, the American Association of Kidney Patients’ Medal of Excellence in 2020 and the American Society of Nephrology’s John P. Peters Lifetime Achievement Award in 2023. In 2025, she was elected to the Association of American Physicians and recognized as a Web of Science Highly Cited Researcher, placing her work among the top 1% most cited in her field.

Dr. Tuttle has authored more than 500 peer-reviewed publications and served as principal investigator on numerous NIH-supported research projects and clinical trials. Her leadership has included major NIH-funded studies including CORAL, CKD-MIT, PERL, and the KPMP and the landmark AWARD-7, FLOW, and REMODEL trials, as well as executive committee roles for major kidney and cardiovascular outcomes trials such as FINE-ONE, FIND-CKD, ZEUS, TRIUMPH-Outcomes, EASi-Kidney and EMPA-KIDNEY.

Dr. Tuttle earned her medical degree from Northwestern University, where she also completed her residency in internal medicine. She completed fellowships in endocrinology and metabolism at Washington University in St. Louis and in nephrology at the University of Texas Health Science Center in San Antonio, creating the multidisciplinary foundation that has defined her career advancing kidney, cardiovascular and metabolic health. A longtime educator and mentor, Dr. Tuttle has trained physician-scientists and clinical investigators for decades while publishing extensively on kidney disease, diabetes and cardiovascular medicine. Through her research, leadership and mentorship, she has helped redefine the prevention and treatment of chronic kidney disease and accelerate the integration of kidney health into cardiovascular care.

Additional Resources:

• Multimedia is available on the right column of the release link.
• For more news at American Heart Association Scientific Sessions 2026, follow us on X @HeartNews, #ScientificSessions26.

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.   

For Media Inquiries:

AHA Communications & Media Relations in Dallas: 214-706-1173; ahacommunications@heart.org

Michelle Kirkwood: michelle.kirkwood@heart.org

For Public Inquiries: 1-800-AHA-USA1 (242-8721)

heart.org and stroke.org

View the original release on www.newmediawire.com